Skip to main content

Advertisement

Table 2 Correlation between mutational status and resistance to anti-EGFR moAb therapy

From: Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients

Mutant genes Responders (CR + PR + SD)a vs non-responders
  Total responders Total non-responders Mutant responders Mutant non-responders P-valueb
KRAS c 37 28 3 8 0.045
NRAS 37 28 1 1 0.999
BRAF 37 28 1 4 0.156
PI3KCA 37 28 2 4 0.389
FBXW7 37 28 1 5 0.077
SMAD4 37 28 1 4 0.156
NRAS/BRAF/PIK3CA d 37 28 3 8 0.045
NRAS/BRAF/PIK3CA/FBXW7 d 37 28 4 11 0.016
NRAS/BRAF/PIK3CA/FBXW7/SMAD4 d 37 28 4 13 0.002
  1. a CR complete response, PR partial response, SD stable disease
  2. b P-value from Fisher's exact test
  3. cPreviously undetected mutations
  4. dSamples with mutations in at least one of the indicated genes